All new products launched in the EU will have to display a black inverted triangle on their product information to denote that the product is subject to additional monitoring if the European Commission accepts the advice of the European Medicines Agency’s new pharmacovigilance committee, the PRAC1.
Under the EU pharmacovigilance legislation of December 2010, the EMA has to draw up a publicly available list of medicines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?